Zhao WY, Zhao JW, Yu L, Yu ZY. Post-endoscopic retrograde cholangiopancreatography pancreatitis: Mechanistic pathways, diagnostic benchmarks, and emerging and mitochondria-targeted therapies. World J Gastrointest Surg 2025; 17(11): 110551 [DOI: 10.4240/wjgs.v17.i11.110551]
Corresponding Author of This Article
Zhong-Yang Yu, PhD, State Key Laboratory of Cardiovascular Diseases, Shanghai East Hospital, School of Medicine, Tongji University, No. 150 Jimo Road, Shanghai 200120, China. 23310158@tongji.edu.cn
Research Domain of This Article
Gerontology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Surg. Nov 27, 2025; 17(11): 110551 Published online Nov 27, 2025. doi: 10.4240/wjgs.v17.i11.110551
Post-endoscopic retrograde cholangiopancreatography pancreatitis: Mechanistic pathways, diagnostic benchmarks, and emerging and mitochondria-targeted therapies
Wei-Yi Zhao, Jin-Wei Zhao, Lu Yu, Zhong-Yang Yu
Wei-Yi Zhao, Department of Pathology, Yanbian Hospital, Yanbian 133002, Jilin Province, China
Jin-Wei Zhao, Department of Hepatopancreatobiliary Surgery, The Second Norman Bethune Hospital of Jilin University, Changchun 130000, Jilin Province, China
Lu Yu, State Key Laboratory for Zoonotic Diseases, Key Laboratory for Zoonosis Research of The Ministry of Education, Institute of Zoonosis, College of Veterinary Medicine, Jilin University, Changchun 130062, Jilin Province, China
Zhong-Yang Yu, State Key Laboratory of Cardiovascular Diseases, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai 200120, China
Author contributions: Zhao WY, Zhao JW, Yu L, and Yu ZY were responsible for writing-original draft, investigation, writing-review & editing, conceptualization, funding acquisition, visualization.
Conflict-of-interest statement: The authors declare that there are no conflicts of interest regarding the publication of this paper.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Zhong-Yang Yu, PhD, State Key Laboratory of Cardiovascular Diseases, Shanghai East Hospital, School of Medicine, Tongji University, No. 150 Jimo Road, Shanghai 200120, China. 23310158@tongji.edu.cn
Received: June 12, 2025 Revised: July 10, 2025 Accepted: October 21, 2025 Published online: November 27, 2025 Processing time: 169 Days and 20 Hours
Core Tip
Core Tip: Post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis is the most common complication of ERCP. Its pathogenesis involves mechanical injury that leads to increased pressure within the pancreatic duct, thereby causing oxidative stress and an inflammatory cascade triggered by dysbiosis. Multiple risk factors are associated with the patient, procedural aspects, and the operator. Prevention strategies primarily focus on patient risk assessment and stratified management, along with optimization of pharmacological treatment and surgical approaches. Advances in treatment emphasize precise interventions and a multidisciplinary collaborative model that integrates medical resources. Future research needs to explore genetic susceptibility, novel targeted therapies, and artificial intelligence-assisted risk assessments.
